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Abstract
Up-regulation of the apoptosis-regulatory gene Mcl-1 (myeloid cell leukemia-1) occurs in different cancer types and is linked
with drug resistance to cancer therapies. It is well known that Mcl-1 pre-mRNA undergoes alternative splicing events to
produce two functionally distinct proteins, Mcl-1S (pro-apoptotic) and Mcl-lL (anti-apoptotic); the latter isoform is
predominant in different cancers including breast and ovarian cancer cells. In the present study we report that the RNA-
binding protein (RBP) and proto-oncogene SRSF1 (serine and arginine-rich splicing factor 1) influences splicing of Mcl-1 in
both MCF-7 and MDA-MB-231 breast cancer cells and JAR choriocarcinoma cells; we also show for the first time that another
RBP SRSF5 affects splicing of Mcl-1 in the MCF-7 cells. Moreover, we report that SRSF1 is involved in other aspects of Mcl-1
regulation with knockdown of SRSF1, by RNAi, resulting in a significant decrease in Mcl-1 protein levels in MCF-7 cells but an
increase in JAR cells, respectively, by potentially affecting protein stability and translation of Mcl-l. The key findings from this
study highlight the importance of the cellular context of different cancer cells for the function of multifunctional RBPs like
SRSF1 and have implications for therapeutic approaches employed to target Mcl-1.
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Introduction
Apoptosis or programmed cell death is an important process
involved in normal development and tissue homeostasis, and its
deregulation can result in cancer. A significant number of
apoptosis factors have been shown to be regulated by alternative
splicing; this includes the Bcl-2 protein family which controls the
intrinsic (mitochondrial) cell death pathway [1,2], Figure 1A. The
Bcl-2 family contains both pro-apoptotic and anti-apoptotic
proteins, and it is the balance between the two which determines
whether the pathway is activated [3,4]. The Bcl-2 family can be
subdivided into three groups based on their structure and function.
The anti-apoptotic Bcl-2 proteins contain multiple Bcl-2 homology
(BH) domains and so are structurally similar to Bcl-2, which is also
a member of this group. The pro-apoptotic Bcl-2 proteins are split
into two subgroups, the first group are also structurally similar to
Bcl-2 with multiple BH domains, and include the proteins Bak and
Bax. The second group of pro-apoptotic proteins only contain the
BH3 domain. Apoptosis is triggered when the pro-apoptotic
proteins Bak and Bax cause mitochondrial outer membrane
permeabilisation. The anti-apoptotic Bcl-2 family members pre-
vent this by binding to the pro-apoptotic proteins Bax and Bak.
The BH3-only proteins can activate apoptosis through two routes
firstly through direct activation of Bak and Bax, and secondly by
binding to the anti-apoptotic proteins, allowing the release of Bak
and Bax.
Mcl-1 is a member of the Bcl-2 family of apoptosis regulators.
Overexpression of Mcl-1 has been found in a wide range of cancer
tissues [5,6,7], as well as cancer cell lines [8]. In addition, increased
expression of Mcl-1 has been associated with poor prognosis in
breast cancer [9]. Mcl-1 also appears to be an important factor
involved in resistance to cancer therapies, and its downregulation
has proved effective at inducing apoptosis [7,10,11,12].
The Mcl-1 gene contains three exons and encodes two proteins,
the anti-apoptotic Mcl-1L and the pro-apoptotic Mcl-1S [13,14].
The full length transcript containing all three exons encodes Mcl-
1L, which contains BH1, 2, and 3 as well as a TM domain. This
results in an anti-apoptotic Bcl-2 protein being produced. Mcl-1S
has the second exon spliced out which results in a downstream
shift in the reading frame leaving only the BH3 domain remaining
(Figure 1B). Mcl-1S appears to exert its pro-apoptotic effect in
a similar way to other BH3-only proteins by binding to anti-
apoptotic Bcl-2 proteins, and more specifically Mcl-1S binds only
to Mcl-1L [13,15].
A switch in the alternative splicing of Mcl-1 has so far been
shown to occur in breast and ovarian cancer, with there being an
increase in the anti-apoptotic Mcl-1L isoform in cancer tissues
[16]. Despite this, very little is known about the mechanism that
regulates the switch in splicing or the splicing factor proteins
involved in the inclusion or exclusion of the second exon. So far
only two members of the SR protein family, SRSF1 and 3, have
been identified as affecting alternate splicing of Mcl-1 [17]. With
relevance to this study a range of different splicing factors have
been shown to have altered expression in cancer tissues [18]; these
include SRSF1 [19] and SRSF3 [20], which are upregulated in
a wide range of cancers and have been identified as proto-
oncogenes, and SRSF5 which is overexpressed in breast cancer
[21].
The aim of the present work was to investigate how Mcl-1 is
regulated in cancer cells and identify cell specific RNA binding
proteins (RBPs) involved in promoting the inclusion of the second
exon of the Mcl-1 gene. This was achieved by using gene specific
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knockdown of a range of different RBPs followed by the
measurement of the levels of the splice-specific isoforms.
Materials and Methods
Cell Culture
Two different cancer cell lines were initially selected for this
study (Figure 2), breast cancer adenocarcinoma MCF-7 cells
(described as having a low invasion phenotype in-vitro) and
choriocarcinoma JAR cells; another breast cancer cell MDA-
MB-231 cells (described as having an invasive phenotype in-vitro)
was added to the study for comparison (ATCC, LCG). MCF-7
and MDA-MB-231 cells were maintained in DMEM (Sigma-
Aldrich) containing 10% foetal calf serum, L-glutamine and
penicillin streptomycin. JAR cells were maintained in RPMI-1640
(ATCC, LCG) containing 10% foetal calf serum and penicillin
streptomycin. Cells were incubated at 37uC with 5% CO2. Cells
were treated with of 20 nM of rapamycin, 35 mg/ml of
cycloheximide or 1 mg/ml protease inhibitor (Sigma-Aldrich)
where indicated.
Gene Knockdown by RNAi
All cells were reverse transfected with SilencerH Select siRNA
(Ambion; Table 1), SilencerH Negative Control siRNA (Ambion),
SilencerH Select GAPDH Positive Control siRNA (Ambion) and
siPORTTM NeoFXTM Transfection Agent (Ambion) using the
following protocol optimised according to the manufacturers
instructions. 5.96104 MCF-7 cells and 46104 JAR cells were
plated into each well of a 24 well plate. JAR cells were transfected
with 4 ul/ml and MCF-7 and MDA-MB-231 cells with 2 ul/ml of
siPORTTM NeoFXTM transfection agent; all cells were transfected
with 6 nM siRNA. Cells and siRNA were incubated together at
37uC in an atmosphere of 5% CO2. RNA was collected 48 and 72
hours post transfection and protein collected 72 hours post
transfection. In all experiments levels of knockdown by RNAi were
assessed at the RNA and protein level by PCR and immunoblot-
ting, as described.
Western Immunoblotting
Cells were washed in ice cold PBS and then collected in RIPA
buffer (25 mM Tris-HCl,pH 7.6, 150 mM NaCl, 1% NP-40,
0.1% sodium deoxycholate and 0.1% SDS) for protein quantifi-
cation followed by the addition of sample buffer and then heat
denatured at 95uC for 5 minutes. Protein lysates were separated
using 12% SDS-polyacrylamide gel electrophoresis (PAGE) gels
and transferred electrophoretically onto a nitrocellulose mem-
branes. Membranes were blocked for 1 hour with PBS containing
10% dried milk powder, and probed with either mouse anti-Mcl-1
(1:500, Santa Cruz), rabbit anti-GAPDH (1:1000, Santa Cruz),
mouse anti-SF2/ASF (1:1000, SRSF1, Zymed), rabbit anti-SC35
(1:100, SRSF2, Abgent), mouse anti-SRp20 (1:1000, SRSF3,
Zymed), rabbit anti-SRp75 (1:500, SRSF4, Abcam), goat anti-
SRp40 (1:500, SRSF5, Zymed), rabbit anti-SRp55 (1:2000,
SRSF6, Aviva Systems Biology) overnight at 4uC. After washing
in PBS the appropriate HRP-conjugated secondary antibodies
diluted in PBS were added. ECL or Super Signal Femto ECL
(Pierce) were used for protein detection. Where indicated,
densitometric analysis was performed using a UVP gel documen-
tation system and quantification performed using ImageJ software.
Data was subsequently analysed using a one-way ANOVA with
Tukeys’ multiple comparison test.
RNA Isolation and Semi-quantitative RT-PCR
Total RNA was extracted with RNeasy spin columns (Qiagen)
and treated with DNase I (Qiagen) following manufacturers
instructions. One mg of total RNA was reverse transcribed using
oligo (dT) primers and Superscript II Reverse Transcriptase (RT)
(Invitrogen, Life Technologies). PCRs were performed with the
cDNA, specific primers (Table 2) and PCR master mix (Promega).
Primers for Mcl-1 were designed to be either side of exon 2 so that
they could detect both Mcl-1S and Mcl-1L and distinguish the two
isoforms by size. (Figure 3A). Negative controls, which lacked RT
during the preparation of the cDNA were included to monitor
genomic contamination. The cDNA products were separated by
electrophoresis on 1.5% (w/v) agarose gels, visualised under UV
following ethidium bromide staining.
Figure 1. Pathway to show how Mcl-1, a member of the Bcl-2
family, influences apoptosis. (A) The intrinsic (mitochondrial) cell
death pathway is controlled by the Bcl-2 protein family, including BH3-
only proteins, anti-apoptotic Bcl-2 proteins, Bax, Bak and Bid. (B) The
Mcl-1 gene consists of three exons; the anti-apoptotic Mcl-1L and the
pro-apoptotic Mcl-1S protein isoforms result from inclusion and
skipping of exon 2 (open box), respectively.
doi:10.1371/journal.pone.0051497.g001
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Real-Time PCR
Real-time PCR was performed on cDNA using inventoried
TaqManH assays (Applied Biosystems) and TaqManH Universal
Master Mix II (Applied Biosystems). Taqman assays were selected
that were specific for each of the splice variants of Mcl-1 as the
probes were designed to span exon boundaries specific to each
splice variant (Mcl-1S - exon boundary 1–3, Mcl-1L - exon
boundary 1–2), and Taqman GAPDH assay was selected as an
endogenous control. The assay was performed in quadruplet and
the PCR amplification was performed using the OneStepPlus real-
time PCR system (Applied Biosystems). All experiments were
performed in triplicate with a minimum of three independent
experiments.
miRNA Isolation and Real-time PCR
Total RNA was extracted with TRIzolH, precipitated with
100% ethanol and then purified on RNeasy spin columns (Qiagen)
using only buffer RPE. Total RNA was eluted from the columns
with RNase free water. Reverse transcription reaction was
performed on 10 ng of total RNA, using TaqManH MicroRNA
Reverse Transcription Kit (Applied Biosystems), and sequence
specific RT primers from the TaqManH Small RNA Assays
(Applied Biosystems) according to manufacturers instructions.
Separate reverse transcription reactions were performed for each
TaqManH Small RNA Assay on every RNA sample. Real-time
PCR was performed on cDNA using inventoried TaqManH Small
RNA Assays and TaqManH Universal Master Mix II (Applied
Biosystems). The assay was performed in triplicate and the PCR
amplification was performed using the OneStepPlus real-time
PCR system (Applied Biosystems).
Apoptosis Assay
MCF-7 cells were reverse transfected with siRNA into 96 well
plates, and then incubated for 48 hours. MCF-7 cells were then
treated with the topoisomerase inhibitor, Etoposide, as previously
described [22]. In brief, cells were incubated with serum starvation
media (1% FCS) for 18 hours, followed by treatment with 200 mM
Etoposide (Sigma Aldrich) for 6 hours [22]. Caspase levels were
then measured using Caspase-Glo 3/7 assay (Promega) according
to manufacturer’s instructions. Briefly equal volumes of Caspase-
Glo 3/7 reagent were added to the wells and incubated at room
temperature for 1 hour and then luminescence was measured on
a luminometer (BMG).
Results
Mcl-1 Splice Isoforms and SR Proteins in Cell Lines
RBPs involved in the control of the alternative splicing event in
Mcl-1 were investigated in both JAR and MCF-7 cells. The
rationale for using these two cell lines was based on the premise
that they have different expression profiles for Mcl-1L and Mcl-1S.
JAR cells produce both Mcl-1L and Mcl-1S, whereas MCF-7 cells
only produce high levels of Mcl-1L (Figure 2, top panel). Cell
lysates from the same cell lines (Figure 2) were also assessed for
expression of a selection of RBPs (SR proteins, SRSF1–6), known
to be involved in splice site selection and predicted to have
putative RNA-binding sites within exon 2 of the Mcl-1 gene
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder). Compari-
sons of the expression levels of these SR proteins in the MCF-7
and JAR cell lines only showed slight increases in SRSF2, 3 and 6
in the MCF-7 cells. Despite there being similar levels of
expression, these SR proteins may still be involved in the
alternative splicing of Mcl-1, as the activity of SR proteins are
controlled by their combined nuclear concentration and activation
states in addition to their overall protein levels.
mRNA Levels of Mcl-1 Splice Isoforms after Knockdown
of RNA Binding Proteins
To identify the RBPs involved in the inclusion of the second
exon of Mcl-1, siRNA was used to knockdown candidate proteins
Figure 2. Expression of Mcl-1 and SR proteins in MCF-7 and
JAR cells. Top panel shows Mcl splice isoforms in commercially
available JAR cell lysate, MCF-7 cells and JAR cells. Detection by western
blotting of Mcl-1 splice variants, SRSF1-6 and the loading control
GAPDH in 40 ug of total cell lysate from MCF-7 and JAR cells.
doi:10.1371/journal.pone.0051497.g002
Table 1. siRNA sequences.
Target
gene Sense Antisense
SRSF1 (1) GGAUAACACUAAGUUUAGAtt UCUAAACUUAGUGUUAUCCag
SRSF1 (2) GCAUCUACGUGGGUAACUUtt AAGUUACCCACGUAGAUGCgg
SRSF2 (1) GCACUAUCCUCUUAGAGAAtt UUCUCUAAGAGGAUAGUGCat
SRSF2 (2) GCACGAAGGUCCAAGUCCAtt UGGACUUGGACCUUCGUGCgg
SRSF3 GCAACAAGACGGAAUUGGAtt UCCAAUUCCGUCUUGUUGCca
SRSF4 GCAUAAAAGUAAGAGCAAAtt UUUGCUCUUACUUUUAUGCtt
SRSF5 (1) CCACCUGUAAGAACAGAAAtt UUUCUGUUCUUACAGGUGGag
SRSF5 (2) GGACGAUACUCUGACCGUUtt AACGGUCAGAGUAUCGUCCtc
SRSF6 (1) CAAAUGAGGGUGUAAUUGAtt UCAAUUACACCCUCAUUUGtt
SRSF6 (2) CGUUCUCGAUCAAAAGGCAtt UGCCUUUUGAUCGAGAACGtg
Tra2B GGAGGAUACAGAUCACGUUtt AACGUGAUCUGUAUCCUCCac
SREK1 (1) CCAACAAUGCAAUAGUAAAtt UUUACUAUUGCAUUGUUGGag
SREK1 (2) GGCCCUUGCUUUUAAUGGAtt UCCAUUAAAAGCAAGGGCCct
Nomenclature and nucleotide sequences of the siRNA oligonucleotides used in
this study.
doi:10.1371/journal.pone.0051497.t001
Regulation of Mcl-1 in Cancer Cells
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e51497
Figure 3. Knockdown of RNA binding proteins in MCF-7 cells and their effect on the mRNA levels of Mcl-1 splice isoforms. MCF-7
cells were transfected with SRSF1-6, Tra2b, SREK1, GAPDH (G) and Negative control (NC) siRNAs, or treated with vehicle (lipid) only (V), or were left
untreated (UT). (A) Semi-quantitative RT-PCR showing both Mcl-1 spliced variants. (B) Semi-quantitative RT-PCR showing knockdown of RNA binding
proteins 48 hours after transfection with siRNAs. (C) Semi-quantitative RT-PCR showing levels of the Mcl-1 splice isoforms (Mcl-1L and Mcl-1S) and the
loading control GAPDH 72 hours after transfection with siRNAs. (D) Mcl-1L levels measured by real-time PCR on the same sample shown in (B). (E)
Mcl-1S levels measured by real-time PCR on the same sample shown in (B). (F Mcl-1S levels in sample replicates measured by real-time PCR (mean
(n = 3) 6 SEM). ** P#0.01; * P#0.01.
doi:10.1371/journal.pone.0051497.g003
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in MCF-7 cells. The RBPs SRSF1, 2, 5, 6 and SR regulatory
protein SREK1 (SFRS12) had two different siRNA which targeted
their sequence whereas SRSF3, 4 and Tra2b had one siRNA. An
important consideration was to first verify that knockdown of
individual SRSFs by RNAi didn’t affect the expression of other
family members (Figure S1). Figure 3B demonstrates the
knockdown of the RBPs in MCF7 cells 48 hours after transfection,
and shows that levels of mRNA for each RBP was reduced by at
least one siRNA. An initial screen of the effect of siRNA-mediated
knockdown by both semi-quantitative PCR (Figure 3C) and real-
time PCR (Figure 3D and 3E) showed that at 72 hours post
transfection levels of Mcl-1S increased when cells were depleted of
SRSF1(1 and 2) and SRSF5 (1); a slight increase in Mcl-1S was
also observed when Tra2b levels were reduced by siRNA.
Although the second siRNA that targeted SRSF5 (2) did not
produce a similar increase in Mcl-1S, the knockdown of SRSF5
was not as effective as with SRSF5 (1) siRNA. Levels of Mcl-1L
RNA were also measured (Figure 3C and 3D), but as the
expression levels of Mcl-1L mRNA were so high the slight changes
produced by the switch in splicing were not observed in the overall
mRNA expression. After the initial screen of siRNAs the
knockdowns were repeated with SRSF1 (1 and 2) and SRSF5 (1)
siRNAs (n= 3), and Figure 2F shows significant up-regulation of
Mcl-1S mRNA 72 hours after transfection of these siRNAs into the
MCF-7 cell line.
To assess which RBPs are involved in this alternative splicing
event in JAR cells, the same panel of siRNAs were used to
knockdown the RBPs in these cells. Figure 4A shows the
knockdown achieved with these siRNAs in JAR cells 48 hours
after transfection. The switch in splicing was assessed by
measuring the mRNA levels of Mcl-1 by semi-quantitative PCR
(Figure 4B) and real-time PCR (Figure 4C and 4D) after 72 hours.
Results show a large increase in the level of Mcl-1S after SRSF1
had been knocked down by either SRSF1 (1) or SRSF1 (2). Mcl-1L
levels were also measured in the screen, but like the MCF-7 cells
no change was observed due to the high levels of Mcl-1L mRNA
present. To validate the results of the initial screen the knockdowns
with SRSF1 (1 and 2) were repeated (n= 3) and showed
a significant increase in the levels of Mcl-1S mRNA after
knockdown of SRSF1 (Figure 4E).
Protein Levels of Mcl-1 Splice Isoforms after Knockdown
of RNA Binding Proteins
To determine whether the switch in splicing observed in the
mRNA was translated into proteins, immunoblotting was used to
define the expression pattern of Mcl-1L and Mcl-1S in MCF-7 and
JAR cells. It is worthy to note that levels of Mcl-1S and Mcl-1L
proteins cannot be visualised, for quantification purposes, at the
same exposure time (Figure S4) due to the low levels of
endogenous Mcl-1S. Knockdown of SRSF1 and SRSF5 in
MCF-7 cells is shown in Figure 5A, along with the resulting
production of small amounts of Mcl-1S, replicating the observa-
tions made of Mcl-1S mRNA levels (Figure 3B and 3D). Protein
levels of Mcl-1L are also shown after knockdown. The levels of
Mcl-1L after treatment with SRSF5 siRNA do not change
significantly from the controls, which is consistent with the mRNA
levels of Mcl-1L after SRSF5 knockdown (Figure 3B and 3C).
Interestingly, the levels of Mcl-1L were significantly reduced after
SRSF1 was knocked down compared to the controls in MCF-7
cells. This reduction observed in the protein levels was not
observed in Mcl-1L mRNA (Figure 3B and 3C), therefore the
reduction in SRSF1 may be affecting the translation or stability of
Mcl-1 as well as the alternative splicing event. Initial data from
immunoprecipitation experiments suggest SRSF1 may bind to
Mcl-1 mRNA in MCF-7 cells (Figure S3 and Methods S1); This
observation is in keeping with previous evidence that SRSF1
protein:Mcl-1 RNA complexes exist [17].
Figure 5B shows the effect on protein levels of Mcl-1 after
treatment with SRSF1 siRNA in JAR cells. Consistent with the
mRNA results, reductions in SRSF1 levels resulted in an increase
in the protein level of Mcl-1S. In contrast, Mcl-1L protein levels
increased after treatment with SRSF1 siRNA, whereas the
corresponding mRNA results did not show any change in levels
after knockdown (Figure 4B and 4C). Consequently, unlike the
MCF-7 cell line, Mcl-1L protein levels increased in response to
SRSF1 siRNA rather than reducing, this increase was not
statistically significant (Figure 4B). These findings indicate that
SRSF1 may be involved in other aspects of Mcl-1 regulation such
as translational control or protein stability in JAR cells. Protein
levels of Mcl-1L and Mcl-1S were also examined after knockdown
with the other RBPs used in the RNA screen in both the MCF-7
and JAR cells, but no changes were observed (data not shown).
We next investigated whether knockdown of SRSF1, which
resulted in such a dramatic change in Mcl-1L and Mcl-1S protein
ratios in the MCF-7 cells, could affect the induction of apoptosis.
Table 2. Primer sequences.
Target gene Forward primer Reverse primer PCR cycles
Mcl-1 59-GGACACAAAGCCAATGGGCAGGT-39 59-GCAAAAGCCAGCAGCACATTCCTGA-39 26/36
SRSF1 59-GCCCCGCAGGGAACAACGAT-39 59-CGTCTCGCGGGTCCTCGAAC-39 26
SRSF2 59-AGTCTCGGTCCCGCACTCGT-39 59-CCAAAGGTGAGTAACCTCCGAGCAG-39 28
SRSF3 59-CGTGTGGATTTGAGCCGCCGC-39 59-TGGAGATCTGCGACGAGGTGGAGGA-39 24
SRSF4 59-GCCAGGTTCCAGACGACGCC-39 59-GCGGCTCTTGCCAGCGCTAT-39 28
SRSF5 59-TTGCGGATGCACACCGACCT-39 59-TCCGGCTCCTGCTCCTGCTT-39 24
SRSF6 59-CTTGCGGTCCGCCGTTCGAC-39 59-GTATCCACCTCCACCACTGCGG-39 26
SREK1 59-TGTGCGGATGGCAGGTGATGAG-39 59-TGGGAACGAGATCGACCGCCTT-39 26
Tra2B 59-GGAGGCGGTGCGGAGCATTT-39 59-TCGCCGCTGTCGCTCATGAC-39 28
GAPDH 59-CTGCCGTCTAGAAAAACC-39 59-CCAAATTCGTTGTCATACC-39 20
Nomenclature and nucleotide sequences of the PCR primer used in this study.
doi:10.1371/journal.pone.0051497.t002
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Figure 4. Knockdown of RNA binding proteins in JAR cells and their effect on the mRNA levels of Mcl-1 splice isoforms. JAR cells were
transfected with SRSF1-6, Tra2b, SREK1, GAPDH (G) and Negative control (NC) siRNAs, or treated with vehicle (lipid) only (V), or were left untreated
(UT). (A) Semi-quantitative RT-PCR showing knockdown of RNA binding proteins 48 hours after transfection with siRNAs. (B) Semi-quantitative RT-
PCR showing levels of the Mcl-1 splice isoforms (Mcl-1L and Mcl-1S) and the loading control GAPDH 72 hours after transfection with siRNAs. (C) Mcl-1L
levels measured by real-time PCR on the same sample shown in (B). (D) Mcl-1S levels measured by real-time PCR on the same sample shown in (B). (E)
Mcl-1S levels in sample replicates measured by real-time PCR (mean (n = 3) 6 SEM). * P#0.01.
doi:10.1371/journal.pone.0051497.g004
Figure 5. Knockdown of RNA binding proteins and their effect on the protein levels of Mcl-1 splice isoforms. (A) MCF-7 cells were
transfected with SRSF1 (1 and 2), SRSF5 (1 and 2), GAPDH (G) and Negative control (NC) siRNAs, or treated with vehicle (lipid) only (V), or were
untreated (UT). SRSF1, 5, Mcl-1 and GAPDH protein levels were determined by immunoblotting 72 hours after transfection with the siRNAs, using
30mg of total cell lysate. Histograms show densitometric analysis of Mcl-1L and Mcl-1S protein expression. Data are shown as the mean 6 SEM. **
indicates P#0.01; * indicates P,0.05. (B) JAR cells were transfected with SRSF1 (1 and 2), GAPDH (G) and Negative control (NC) siRNAs, or treated
with vehicle (lipid) only (V), or were untreated (UT). SRSF1, Mcl-1 and GAPDH protein levels were determined by immunoblotting 72 hours after
transfection with the siRNAs, using 30 mg of total cell lysate. (C) After transfection with SRSF1 (1) and NC siRNA MCF-7 cells were treated with 200 mM
etoposide or DMSO control for 6 hours. Induction of apoptosis was assessed by measuring caspase3/7 activity.* indicates P,0.05.
doi:10.1371/journal.pone.0051497.g005
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We first performed a MTT assay to rule out the possibility that cell
proliferation and cell viability may be affected by knockdown of
SRSF1 in the MCF-7 cells (Figure S2 and Methods S2). Apoptosis
was induced in both the negative control and SRSF1 (1) siRNA
treated cells by treatment with etoposide (200 mM), and measured
by assessing the resulting caspase 3/7 activity (Figure 5C). The
percentage increase in caspase 3/7 activity was slightly higher after
knockdown of SRSF1 demonstrating a greater induction of
apoptosis.
Effect of SRSF1 Knockdown on Stability and Translation
of Mcl-1L
Mcl-1 contains multiple residues within the N-terminal region
that can undergo post translational modification, such as
ubiquitination and phosphorylation [23]. These modifications
can affect the stability of the Mcl-1 protein. Therefore, we went on
to assess the stability of Mcl-1 protein after knockdown of SRSF1
in the two cell lines. Cycloheximide treatment was used to block
protein translation and Mcl-1L protein levels were assessed over
the following 7 hours. Figure 6A shows a very similar rate of loss of
Mcl-1L in the MCF-7 cells after treatment with SRSF1 siRNA
compared with negative control siRNA. This suggests that there is
no change in the stability of Mcl-1L after knockdown of SRSF1 in
the MCF-7 cells. In contrast, treatment of the JAR cells with
cycloheximide (Figure 6B) resulted in slightly slower rate of loss of
Mcl-1L after knockdown of SRSF1, indicating that there may be
a slight increase in Mcl-1L protein stability.
As the decrease in the levels of Mcl-1L in the MCF-7 cells after
SRSF1 knockdown does not appear to be affecting the stability of
the protein, it may be a translational effect. SRSF1 has already
been demonstrated to be involved in mTOR translation initiation,
where its presence on the RNA results in enhanced recruitment of
the mTOR complex to the mRNA [24,25,26,27,28]. Additionally,
Mcl-1 has also been shown to be translationally controlled by
mTOR and the mTOR signalling pathway [24,25,26,27,28]. To
further investigate this, MCF-7 cells were treated with the mTOR
inhibitor rapamycin. Figure 6C confirms the reduction in Mcl-1L
after treatment with rapamycin and shows this reduction in Mcl-
1L to be similar to that observed after SRSF1 knockdown.
Furthermore, the addition of rapamycin to the SRSF1 knockdown
cells did not result in any further decrease in the levels of Mcl-1L.
A recent report has also suggested another mechanism by which
SRSF1 can control translation, through the processing of miRNAs
[29]. One of the miRNAs identified as being upregulated after
overexpression of SRSF1 was mir-29b. This miRNA has already
been shown to be involved in the translational inhibition of Mcl-1
[30]. In light of this we hypothesised the increase observed in Mcl-
1L protein levels in the JAR cells may, in part, be due to decreased
levels of mir-29b. As the knockdown of SRSF1 in the MCF-7 cells
did not show a similar increase in the levels of Mcl-1L protein but
in fact a decrease, we would not expect mir-29b to be involved in
the regulation of Mcl-1L in MCF-7 cells. As a result the initial
levels of mir-29b might be expected to be higher in JAR cells
compared to MCF-7 cells. To investigate this mir-29b was
measured in untreated JAR and MCF-7 cells by real-time PCR
(Figure 6D). This showed, contrary to expectation, that levels of
mir-29b were significantly higher in the MCF-7 cells compared to
the JAR cells. To assess whether the knockdown of SRSF1 affected
the levels of mir-29b, as over-expression has previously been
shown to do this [29], siRNA was used to knockdown SRSF1 in
MCF-7 cells (Figure 6E) and JAR cells (Figure 6F). The
knockdown was initially performed in MCF-7 cells since they
showed the highest initial levels of mir-29b (Figure 6D). Although
treatment with the transfection reagent alone seemed to result in
a reduction in mir-29b in MCF-7 cells, knockdown of SRSF1 had
little effect on the levels of mir-29b in both cell types when
compared with the negative control siRNA transfected cells
(Figure 6E and 6F).
Regulation of Mcl-1 by SRSF1 and 5 was also investigated in
a second breast cancer cell line using MDA-MB-231 cells,
described as having an invasive phenotype in vitro. Endogenous
Mcl-1 protein levels were assessed by western blotting (Figure 7A),
indicating that MDA-MB-231 cells express mainly the Mcl-1L
protein isoform, but at much lower levels than MCF-7 cells. To
determine whether the same RBPs are involved in the splicing of
Mcl-1 in MDA-MB-231 cells siRNA against SRSF1 and 5 was
used to deplete cells of these two proteins. Figure 7B shows
a reduction in the RNA levels of SRSF1 and 5 after 48 hours, and
a subsequent increase in the levels of Mcl-1S mRNA after 72
hours. Real time PCR analysis of repeated transfections also
demonstrated a significant upregulation of Mcl-1S mRNA 72
hours after transfection with both SRSF1 and 5 siRNAs. Protein
levels were also measured by immunoblotting after knockdown of
SRSF1 and 5. Figure 7C shows knock down of SRSF1 and 5
proteins 72 hours after transfection. Due to the low levels of Mcl-
1L and Mcl-1S in the MDA-MB-231 cell line Super Signal Femto
ECL was used to detect the two isoforms, but this failed to show
any significant change in the two isoforms after knockdown of
SRSF1 or 5, although there was a slight reduction in Mcl-1 protein
after knockdown of both SR proteins (Figure 7C). As the mTOR
pathway appears to be important in the regulation of Mcl-1 in
MCF-7 cells this was also investigated in the MDA-MB-231 cells.
Rapamycin was used to inhibit the mTOR pathway in this cell
line, but the dramatic reduction that was observed in the MCF-7
cells with rapamycin treatment and SRSF1 knockdown was not
less evident with the MDA-MB-231 cells.
Discussion
The results presented here as well as the study by Moore, M
et al [17] provide increasing evidence for the central role of
SRSF1 in the control of the alternative splicing of Mcl-1.
Previously SRSF1 has been identified as a proto-oncogene with
increased expression in a wide variety of tumours [19], and in
addition has been demonstrated to be involved in cancer
associated changes in alternative splicing. With relevance to breast
cancer progression, alternative splicing events mediated by SRSF1
are capable of promoting mammary gland tumorigenesis [31].
More specifically, SRSF1 has been shown to affect the alternative
splicing of the tumour suppressor Bin1 [19,31], kinases (S6K1 and
Mnk2) [19], transcripts involved with cell mobility (Ron [31,32]
and Rac1 [33]), proliferation (Cyclin D1 [34]) and apoptosis (Bcl-x
[17]) and Bim (also known as BCL2L11) [31]. The involvement of
SRSF1 in the production of the anti-apoptotic of Mcl-1 in breast
cancer cells adds to the number of cancer specific splicing events
controlled by this SR protein.
The other splicing factor identified in this study as influencing
the splicing of Mcl-1 was SRSF5. This is the first time this SR
protein has been linked with the alternative splicing of Mcl-1.
Previously SRSF5 expression has been shown to be increased in
breast cancer, where it was associated with changes in alternative
splicing of CD44 as well as lymph node metastasis [21]. So its
involvement in the production of the anti-apoptotic form of Mcl-1
in the MCF-7 and MDA-MB-231 breast cancer cell lines is
consistent with its known upregulation in breast cancer tissue.
Despite the clear involvement of SRSF5 in MCF-7 and MDA-
MB-231 breast cancer cells, this SR protein did not appear to be
involved in the alternative splicing of Mcl-1 in JAR cells. However,
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we cannot rule out that this difference is due to SRSF5 not being
sufficiently knocked down in the JAR cells, as a result of the
reduced transfection efficiency of this cell line. Other SR proteins
previously implicated in the splicing of Mcl-1 include SRSF3 and
Tra2b. This study found no effect on the splicing pattern of Mcl-1
after knockdown of SRSF3 in either JAR or MCF-7 cells, and only
a very slight increase in Mcl-1S mRNA levels in MCF-7 cells after
knockdown of Tra2b. In contrast, Moore, et al [17] found that
knockdown of SRSF3 and Tra2b in HeLa cells affected the
alternative splicing pattern of a Mcl-1 reporter construct. Taken
together these findings indicate that different splicing factors are
involved in the selection of splice sites in the Mcl-1 transcript in
different cellular contexts.
Figure 6. Effect of SRSF1 knockdown on expression, stability and translation of Mcl-1L in MCF-7 and JAR cells. (A) MCF-7 and (B) JAR
cells were transfected with SRSF1 (1 and 2) and negative control (NC) siRNA. Three days after transfection cells were treated with 35 ug/ml
cycloheximide and protein samples were collected after 0, 0.5, 1, 1.5, 2, 3, 5 and 7 hours to assess protein stability. Mcl-1L protein levels were then
measured by immunoblotting. (C) MCF-7 cells were transfected with SRSF1 (1 and 2), GAPDH (G) and negative control (NC) siRNA, or treated with
vehicle (lipid) only (V), or were untreated (UT). 48 hours after transfection cells were treated with 20 nM rapamycin for a further 24 hours. Western
blotting was then used to assess protein levels of SRSF1, Mcl-1L and GAPDH. (D) mir-29b levels measured by real-time PCR in JAR and MCF-7 cell lines
(mean (n = 3) 6 SEM), ** P#0.01. Knockdown of SRSF1 in MCF-7 cells (E) and JAR cells (F) was assessed by semi-quantitative RT-PCR in SRSF1 (1) and
negative control (NC) siRNA (upper panels). Levels of mir-29b were measured by real-time PCR in SRSF1 (1) and negative control (NC) siRNA treated
MCF-7 cells from (E) and JAR cells from (F) along with GAPDH (G) siRNA, vehicle (lipid) only (V), and untreated (UT) cells (lower panels) (mean (n = 3)6
SEM).
doi:10.1371/journal.pone.0051497.g006
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In addition to demonstrating the role of SRSF1 in the
alternative splicing of Mcl-1 we also show its involvement in
other aspects of Mcl-1 regulation. Knockdown of SRSF1 resulted
in a decrease in Mcl-1 in the breast cancer cell lines studied and an
increase in the choriocarcinoma cells, and achieved this by both
affecting protein stability and translation of Mcl-1. In the JAR
cells, knockdown of SRSF1 resulted in a slight increase in the
stability of Mcl-1L protein. Mcl-1 is an unstable protein which has
a relatively short half life, due to the PEST regions within its N-
terminal. This N-terminal region contains residues which are
phosphorylated resulting in both increases and decreases in the
protein’s stability, as well as sites of ubiquitination and cleavage
[23]. All these post-translational modifications of Mcl-1 affect the
rate of turnover, and therefore in the future it will be interesting to
investigate whether they are targeted by SRSF1, and if so the
mechanism involved.
SRSF1 was also shown to be involved in the translational
control of Mcl-1 in MCF-7 cells, as the knockdown of SRSF1 had
no observable effect on the stability of Mcl-1L. The data presented
here indicates that this translational effect may be mediated by
interactions with the mTOR complex. The mTOR signalling
pathway is involved in controlling cell proliferation, growth and
survival, and its dysregulation has been shown to commonly occur
in cancers. As a result there are a number of mTOR inhibitors
Figure 7. Effect of SRSF1 and SRSF5 knockdown on expression, stability and translation of Mcl-1L in MDA-MB-231 cells. (A) Detection
of Mcl-1 splice variants and GADPH proteins in MCF-7 and MDA-MB-231 using 40 ug of total cell lysate from both cell types. Histograms show
densitometric analysis of Mcl-1L and Mcl-1S protein expression. Data are shown as the mean 6 SEM. (B) Semi-quantitative RT-PCR showing
knockdown of RNA binding proteins 48 hours after transfection with siRNAs. MDA-MB-231 cells were transfected with SRSF1, GAPDH (G) and
Negative control (NC) siRNAs, or treated with vehicle (lipid) only (V), or were left untreated (UT). Semi-quantitative RT-PCR showing levels of the Mcl-1
splice isoforms (Mcl-1L and Mcl-1S) and the loading control GAPDH 72 hours after transfection with siRNAs. Mcl-1S levels in sample replicates
measured by real-time PCR (mean (n = 3) 6 SEM). (C) MDA-MB-231 cells were transfected with SRSF1, SRSF5, GAPDH (G) and Negative control (NC)
siRNAs, or treated with vehicle (lipid) only (V), or were untreated (UT). SRSF1, 5, Mcl-1 and GAPDH protein levels were determined by immunoblotting
72 hours after transfection with the siRNAs, using 30 mg of total cell lysate. (D) MDA-MB-231 cells were transfected with SRSF1, GAPDH (G) and
negative control (NC) siRNA, or treated with vehicle (lipid) only (V), or were untreated (UT). 48 hours after transfection cells were treated with 20 nM
rapamycin for a further 24 hours. Immunoblotting was then used to assess protein levels of SRSF1, Mcl-1L and GAPDH (mean (n = 3) 6 SEM). ***
indicates P#0.001; ** P#0.01.
doi:10.1371/journal.pone.0051497.g007
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currently undergoing clinical trials. Here we confirm previous
reports of Mcl-1 being a target of mTOR mediated translation
initiation [27,28,35], as the mTOR inhibitor rapamycin decreased
Mcl-1 protein levels in control cells. There is also growing
evidence for the involvement of SRSF1 in activating the mTOR
pathway through recruitment of the mTOR complex to the
mRNA, resulting in increased translation [24,25,26]. In this
context, Michlewski et al demonstrated that SRSF1 influences
translation initiation by enhancing phosphorylation of the trans-
lation inhibitor 4E-BP1 and reducing its activity [25]. The results
we present here further implicate Mcl-1-L as a potential target for
this process of SRSF1 mediated mTOR translation initiation.
Although the knockdown of SRSF1 does appear to affect the
stability of Mcl-1L we also investigated a possible mechanism of
translational control in this cell line. A previous study had
identified mir-29b as being upregulated as a result of enhanced
processing, in response to SRSF1 overexpression [29]. This same
miRNA had also been demonstrated to control the translation of
Mcl-1 [30]. Despite this link we did not find any direct evidence
for mir-29b being involved in controlling translation of Mcl-1 in
JAR cells, as levels of mir-29b were so much lower in these cells
compared to MCF-7 cells. In addition, the knockdown of SRSF1
in MCF-7 cells had very little effect on the levels of mir-29b.
Although mir-29b may not be affected by SRSF1 in these cells
there remains the possibility that SRSF1 is involved in the
processing of another miRNA that also targets Mcl-1 in this cell
line, or that SRSF1 is involved in other mechanisms of trans-
lational repression.
We also evaluated whether the observed changes in Mcl-1L and
Mcl-1S expression as a consequence of SRSF1 knockdown
impacted on cell apoptosis; we observed a modest increase in
caspase activity in MCF-7 cells. However, despite an increase in
Mcl-lS expression when cancer cells were depleted of SRSF1 the
relative levels of pro-apoptotic McL-1S compared to those of anti-
apoptotic Mcl-1L remained low. This expression profile is
consistent with previous work reporting reduced expression of
endogenous Mcl-1S in cancer cell lines [36]. It is pertinent that
elevated levels of Mcl-lS can induce apoptosis when artificially
overexpressed using either a Mcl-1S gene construct [13] or
antisense morpholino oligonucleotides that target Mcl-1 pre-
mRNA and switch splice-site selection to shift expression from
Mcl-1L to Mcl-1S [36]. In light of this it is probable that in the
present study the decrease in Mcl-1L explains the slight increase in
cell death as opposed to the increase in the pro-apoptotic Mcl-1S
isoform. Moreover, it could be reasoned that other pro-apoptotic
proteins regulated by SRSF1 may also be involved [31].
In summary, the findings from this study demonstrate the
importance of the cellular context for the function of multifunc-
tional RNA binding proteins like SRSF1, and have important
implications for therapeutic approaches employed to target Mcl-1.
For example, in breast tumour cells with similar cellular
environments to the MCF-7 cells, the knockdown of SRSF1
may provide a powerful way of inducing apoptosis, as there is both
a switch in splicing and a reduction in translation of Mcl-1L
protein. However in a cellular environment similar to the JAR
choriocarcinoma cells this dual effect is not observed. Therefore,
in the future it is important to try and understand the mechanisms
involved in controlling the functions of SRSF1 in different cell
types. These may include differences in the phosphorylation state
of the RS domain, which controls its subcellular localisation and
activation state, the presence of different binding partners and
coregulators, or differences in activation of signalling pathways
such as the mTOR pathway. Understanding these mechanisms
may also provide further opportunities for affecting Mcl-1 splicing,
translation and stability, and therefore ways of inducing apoptosis
in cancer cells.
Supporting Information
Figure S1 Knockdown of RNA-binding proteins. (A)
Semi-quantitative RT-PCR showing knockdown 48 hours after
transfection with siRNAs in MCF-7 cells and their effect on the
mRNA levels of Mcl-1 splice isoforms (Mcl-1L and Mcl-1S) and the
loading control GAPDH. MCF-7 cells were transfected with
SRSF1, 2, 5, 6, SREK1, GAPDH (G) and Negative control (NC)
siRNAs, or treated with vehicle (lipid) only (V), or were left
untreated (UT). (B) Semi-quantitative RT-PCR of the loading
control GAPDH 48 hours after JAR cells were transfected with
SRSF1-6, Tra2b, SREK1, GAPDH (G) and Negative control
(NC) siRNAs, or treated with vehicle (lipid) only (V), or were left
untreated (UT).
(TIF)
Figure S2 Cell proliferation after SRSF1 knockdown.
Cell proliferation was determined by MTT assay 72 hours after
MCF-7 cells were transfected with SRSF1 (1) and Negative control
(NC) siRNAs. Results show mean (n = 6) 6 SEM.
(TIF)
Figure S3 SRSF1 interactions with Mcl-l mRNA. Immu-
noprecipitation with anti-SRSF1 antibody (SRSF1 Ab), an isotype
control antibody (IgG Ab) or without antibody (No Ab) was
performed with MCF-7 cell lysate. Bound Mcl-1 mRNA
transcripts were detected by RT-PCR, MCF-7 total RNA was
also used as a positive control.
(TIF)
Figure S4 Expression of Mcl-1 proteins in MCF-7 cells.
(A) Detection by immunoblotting of Mcl-1L protein and the
loading control GAPDH in 40 ug of total cell lysate from MCF-7
using ECL detection reagent (Pierce). (B) Detection of Mcl-LS on
the same membrane was achieved using an alternative and more
sensitive procedure using SuperSignal West Femto ECL detection
reagent (Pierce).
(TIF)
Methods S1 Immunoprecipitation and RNA Isolation.
MCF-7 cells were washed in ice cold PBS and then collected in
lysis buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-
40, 1% Triton X-100) containing protease inhibitors (Sigma-
Aldrich). Dynabeads Protein A (Invitrogen) were incubated for 3
hours at 4uC with 10 mg of antibody (mouse anti-SF2/ASF
(SRSF1, Zymed) and mouse IgG control (Santa Cruz)) diluted in
lysis buffer or with lysis buffer alone. Beads were then washed
three times with lysis buffer before being incubated for 1 hour at
4uC with the cell lysate. Beads were then washed five times with
lysis buffer before the immunoprecipitated RNA was collected in
Trizol reagent (Invitrogen) according to manufacturer’s instruc-
tions. The RT-PCR was performed as before but half of the RNA
obtained from the immunoprecipitation was used in each reaction.
(DOCX)
Methods S2 MTT Cell Proliferation Assay. MCF-7 cells
were seeded and transfected with siRNA as before. After 72 hours
proliferation was measured using TACS MTT Cell Proliferation
Assay (Trevigen), according to manufacturer’s instructions.
(DOCX)
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